Insulin-like growth factor binding protein-5 in osteogenesis: Facilitator or inhibitor?

Growth Hormone and IGF Research

Volumn 17, Issue 3, 2007, Pages 179-185

  Mukherjee, Aditi ^a   Rotwein, Peter ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN BINDING PROTEIN 6; SOMATOMEDIN RECEPTOR;

BIOSYNTHESIS; BONE DEVELOPMENT; BONE MINERALIZATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CORTICAL BONE; EXPERIMENTAL DESIGN; HUMAN; METHODOLOGY; NONHUMAN; OSTEOBLAST; PHYSICAL DEVELOPMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW;

ANIMALS; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 5; OSTEOGENESIS; PROTEIN CONFORMATION;

EID: 34250004672     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2007.01.005     Document Type: Review

References (49)

1. Beattie J., Allan G.J., Lochrie J.D., and Flint D.J. Insulin-like growth factor-binding protein-5 (IGFBP-5): a critical member of the IGF axis. Biochem. J. 395 (2006) 1-19
2. Clemmons D.R. Role of insulin-like growth factor binding proteins in controlling IGF actions. Mol. Cell Endocrinol. 140 (1998) 19-24
3. LeRoith D., Werner H., Neuenschwander S., Kalebic T., and Helman L.J. The role of the insulin-like growth factor-I receptor in cancer. Ann. N.Y. Acad. Sci. 766 (1995) 402-408
4. Mohan S., and Baylink D.J. IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms. J. Endocrinol. 175 (2002) 19-31
5. Firth S.M., and Baxter R.C. Cellular actions of the insulin-like growth factor binding proteins. Endocr. Rev. 23 (2002) 824-854
6. Schedlich L.J., Young T.F., Firth S.M., and Baxter R.C. Insulin-like growth factor-binding protein (IGFBP)-3 and IGFBP-5 share a common nuclear transport pathway in T47D human breast carcinoma cells. J. Biol. Chem. 273 (1998) 18347-18352
7. Schneider M.R., Wolf E., Hoeflich A., and Lahm H. IGF-binding protein-5: flexible player in the IGF system and effector on its own. J. Endocrinol. 172 (2002) 423-440
8. Imai Y., Moralez A., Andag U., Clarke J.B., Busby Jr. W.H., and Clemmons D.R. Substitutions for hydrophobic amino acids in the N-terminal domains of IGFBP-3 and -5 markedly reduce IGF-I binding and alter their biologic actions. J. Biol. Chem. 275 (2000) 18188-18194
9. Kalus W., Zweckstetter M., Renner C., Sanchez Y., Georgescu J., Grol M., Demuth D., Schumacher R., Dony C., Lang K., and Holak T.A. Structure of the IGF-binding domain of the insulin-like growth factor-binding protein-5 (IGFBP-5): implications for IGF and IGF-I receptor interactions. EMBO J. 17 (1998) 6558-6572
10. Arai T., Parker A., Busby Jr. W., and Clemmons D.R. Heparin, heparan sulfate, and dermatan sulfate regulate formation of the insulin-like growth factor-I and insulin-like growth factor-binding protein complexes. J. Biol. Chem. 269 (1994) 20388-20393
11. Parker A., Clarke J.B., Busby Jr. W.H., and Clemmons D.R. Identification of the extracellular matrix binding sites for insulin-like growth factor-binding protein 5. J. Biol. Chem. 271 (1996) 13523-13529
12. Song H., Beattie J., Campbell I.W., and Allan G.J. Overlap of IGF- and heparin-binding sites in rat IGF-binding protein-5. J. Mol. Endocrinol. 24 (2000) 43-51
13. Twigg S.M., Kiefer M.C., Zapf J., and Baxter R.C. Insulin-like growth factor-binding protein 5 complexes with the acid-labile subunit. Role of the carboxyl-terminal domain. J. Biol. Chem. 273 (1998) 28791-28798
14. Twigg S.M., and Baxter R.C. Insulin-like growth factor (IGF)-binding protein 5 forms an alternative ternary complex with IGFs and the acid-labile subunit. J. Biol. Chem. 273 (1998) 6074-6079
15. Andress D.L., Loop S.M., Zapf J., and Kiefer M.C. Carboxy-truncated insulin-like growth factor binding protein-5 stimulates mitogenesis in osteoblast-like cells. Biochem. Biophys. Res. Commun. 195 (1993) 25-30
16. Andress D.L., and Birnbaum R.S. Human osteoblast-derived insulin-like growth factor (IGF) binding protein-5 stimulates osteoblast mitogenesis and potentiates IGF action. J. Biol. Chem. 267 (1992) 22467-22472
17. Mohan S., Thompson G.R., Amaar Y.G., Hathaway G., Tschesche H., and Baylink D.J. ADAM-9 is an insulin-like growth factor binding protein-5 protease produced and secreted by human osteoblasts. Biochemistry 41 (2002) 15394-15403
18. Thrailkill K.M., Quarles L.D., Nagase H., Suzuki K., Serra D.M., and Fowlkes J.L. Characterization of insulin-like growth factor-binding protein 5-degrading proteases produced throughout murine osteoblast differentiation. Endocrinology 136 (1995) 3527-3533
19. Conover C.A., and Kiefer M.C. Regulation and biological effect of endogenous insulin-like growth factor binding protein-5 in human osteoblastic cells. J. Clin. Endocrinol. Metab. 76 (1993) 1153-1159
20. Coverley J.A., and Baxter R.C. Phosphorylation of insulin-like growth factor binding proteins. Mol. Cell Endocrinol. 128 (1997) 1-5
21. Liu J.P., Baker J., Perkins A.S., Robertson E.J., and Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 75 (1993) 59-72
22. Zhang M., Xuan S., Bouxsein M.L., von S.D., Akeno N., Faugere M.C., Malluche H., Zhao G., Rosen C.J., Efstratiadis A., and Clemens T.L. Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J. Biol. Chem. 277 (2002) 44005-44012
23. Zhao G., Monier-Faugere M.C., Langub M.C., Geng Z., Nakayama T., Pike J.W., Chernausek S.D., Rosen C.J., Donahue L.R., Malluche H.H., Fagin J.A., and Clemens T.L. Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation. Endocrinology 141 (2000) 2674-2682
24. Jiang J., Lichtler A.C., Gronowicz G.A., Adams D.J., Clark S.H., Rosen C.J., and Kream B.E. Transgenic mice with osteoblast-targeted insulin-like growth factor-I show increased bone remodeling. Bone 39 (2006) 494-504
25. Ohlsson C., Bengtsson B.A., Isaksson O.G., Andreassen T.T., and Slootweg M.C. Growth hormone and bone. Endocr. Rev. 19 (1998) 55-79
26. Sims N.A., Clement-Lacroix P., Da P.F., Bouali Y., Binart N., Moriggl R., Goffin V., Coschigano K., Gaillard-Kelly M., Kopchick J., Baron R., and Kelly P.A. Bone homeostasis in growth hormone receptor-null mice is restored by IGF-I but independent of Stat5. J. Clin. Invest. 106 (2000) 1095-1103
27. Bautista C.M., Baylink D.J., and Mohan S. Isolation of a novel insulin-like growth factor (IGF) binding protein from human bone: a potential candidate for fixing IGF-II in human bone. Biochem. Biophys. Res. Commun. 176 (1991) 756-763
28. Olney R.C., and Mougey E.B. Expression of the components of the insulin-like growth factor axis across the growth-plate. Mol. Cell Endocrinol. 156 (1999) 63-71
29. Kiepe D., Andress D.L., Mohan S., Standker L., Ulinski T., Himmele R., Mehls O., and Tonshoff B. Intact IGF-binding protein-4 and -5 and their respective fragments isolated from chronic renal failure serum differentially modulate IGF-I actions in cultured growth plate chondrocytes. J. Am. Soc. Nephrol. 12 (2001) 2400-2410
30. Birnbaum R.S., and Wiren K.M. Changes in insulin-like growth factor-binding protein expression and secretion during the proliferation, differentiation, and mineralization of primary cultures of rat osteoblasts. Endocrinology 135 (1994) 223-230
31. Malpe R., Baylink D.J., Linkhart T.A., Wergedal J.E., and Mohan S. Insulin-like growth factor (IGF)-I, -II, IGF binding proteins (IGFBP)-3, -4, and -5 levels in the conditioned media of normal human bone cells are skeletal site-dependent. J. Bone Miner. Res. 12 (1997) 423-430
32. Schmid C., Schlapfer I., Gosteli-Peter M.A., Froesch E.R., and Zapf J. Expression, effects, and fate of IGFBP-5 are different in normal and malignant osteoblastic cells. Prog. Growth Factor Res. 6 (1995) 167-173
33. Gabbitas B., and Canalis E. Insulin-like growth factors sustain insulin-like growth factor-binding protein-5 expression in osteoblasts. Am. J. Physiol. 275 (1998) E222-E228
34. McCarthy T.L., Casinghino S., Centrella M., and Canalis E. Complex pattern of insulin-like growth factor binding protein expression in primary rat osteoblast enriched cultures: regulation by prostaglandin E2, growth hormone, and the insulin-like growth factors. J. Cell Physiol. 160 (1994) 163-175
35. Pash J.M., and Canalis E. Transcriptional regulation of insulin-like growth factor-binding protein-5 by prostaglandin E2 in osteoblast cells. Endocrinology 137 (1996) 2375-2382
36. Schmid C., Schlapfer I., Gosteli-Peter M.A., Hauri C., Froesch E.R., and Zapf J. 1 alpha,25-dihydroxyvitamin D3 increases IGF binding protein-5 expression in cultured osteoblasts. FEBS Lett. 392 (1996) 21-24
37. Canalis E., and Gabbitas B. Skeletal growth factors regulate the synthesis of insulin-like growth factor binding protein-5 in bone cell cultures. J. Biol. Chem. 270 (1995) 10771-10776
38. Rutter M.M., Markoff E., Clayton L., Akeno N., Zhao G., Clemens T.L., and Chernausek S.D. Osteoblast-specific expression of insulin-like growth factor-1 in bone of transgenic mice induces insulin-like growth factor binding protein-5. Bone 36 (2005) 224-231
39. Bauss F., Lang K., Dony C., and Kling L. The complex of recombinant human insulin-like growth factor-I (rhIGF-I) and its binding protein-5 (IGFBP-5) induces local bone formation in murine calvariae and in rat cortical bone after local or systemic administration. Growth Horm. IGF. Res. 11 (2001) 1-9
40. Miyakoshi N., Richman C., Kasukawa Y., Linkhart T.A., Baylink D.J., and Mohan S. Evidence that IGF-binding protein-5 functions as a growth factor. J. Clin. Invest. 107 (2001) 73-81
41. Richman C., Baylink D.J., Lang K., Dony C., and Mohan S. Recombinant human insulin-like growth factor-binding protein-5 stimulates bone formation parameters in vitro and in vivo. Endocrinology 140 (1999) 4699-4705
42. Miyakoshi N., Richman C., Qin X., Baylink D.J., and Mohan S. Effects of recombinant insulin-like growth factor-binding protein-4 on bone formation parameters in mice. Endocrinology 140 (1999) 5719-5728
43. Mohan S., Nakao Y., Honda Y., Landale E., Leser U., Dony C., Lang K., and Baylink D.J. Studies on the mechanisms by which insulin-like growth factor (IGF) binding protein-4 (IGFBP-4) and IGFBP-5 modulate IGF actions in bone cells. J. Biol. Chem. 270 (1995) 20424-20431
44. Schneider M.R., Zhou R., Hoeflich A., Krebs O., Schmidt J., Mohan S., Wolf E., and Lahm H. Insulin-like growth factor-binding protein-5 inhibits growth and induces differentiation of mouse osteosarcoma cells. Biochem. Biophys. Res. Commun. 288 (2001) 435-442
45. Devlin R.D., Du Z., Buccilli V., Jorgetti V., and Canalis E. Transgenic mice overexpressing insulin-like growth factor binding protein-5 display transiently decreased osteoblastic function and osteopenia. Endocrinology 143 (2002) 3955-3962
46. Salih D.A., Mohan S., Kasukawa Y., Tripathi G., Lovett F.A., Anderson N.F., Carter E.J., Wergedal J.E., Baylink D.J., and Pell J.M. Insulin-like growth factor-binding protein-5 induces a gender-related decrease in bone mineral density in transgenic mice. Endocrinology 146 (2005) 931-940
47. Durant D., Pereira R.M., and Canalis E. Overexpression of insulin-like growth factor binding protein-5 decreases osteoblastic function in vitro. Bone 35 (2004) 1256-1262
48. Kanatani M., Sugimoto T., Nishiyama K., and Chihara K. Stimulatory effect of insulin-like growth factor binding protein-5 on mouse osteoclast formation and osteoclastic bone-resorbing activity. J. Bone Miner. Res. 15 (2000) 902-910
49. Andress D.L. Insulin-like growth factor-binding protein-5 (IGFBP-5) stimulates phosphorylation of the IGFBP-5 receptor. Am. J. Physiol. 274 (1998) E744-E750